SNY - Earnings call transcript Q1 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Eva Schaefer-Jansen

Good morning, good afternoon and good evening to everyone. Thank you for joining us to review Sanofi's 2022 first quarter results followed by a Q&A session.

As usual, you can find the slides to this earnings call on the Investors page of our website at sanofi.com.

Moving to Slide 3. I would like to remind you that information presented in this call contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. our also document for our of risk to the file a you these and SEC Document factors. refer Form on XX-F with description I d'Enregistrement Universel Slide to advance please that, With X.

Chief Reed, are on speakers Chief and Jean-Baptiste R&D; Bill Unit the and Global today Sibold, Olivier Chatillon, Global Our Julie Paul Thomas van of Head Ongevalle; Financial Triomphe, call Executive Hudson, Officer; Business Officer. Heads, the John Charmeil de and

the questions click hand options Or at to the screen. For the to I'd the participate. of icon Q&A With the of Q&A, have bottom Paul. like X, at turn you option X Option X, by icon raise your call screen. the to that, bottom submit the your clicking over

Paul Hudson

introduction. for financial of members the you Eva. to to updates thanks business Delighted today. on you, take joining our call executive here thank and performance. with everyone be our through team to Well, Great together our the the And and

sales QX market expectations truly quarter. the of exceeded businesses with in up excited our EPS The X.X% strong start growth first and results outstanding view. top with on the Let's XX.X%. the performance about we're line Well,

double-digit at and annualizing Care to Specialty continues posted the €X billion. remarkable to strong close in grow business Dupixent pace. high ex Our U.S. now growth U.S. a sales

and In billion to recovery Play rates U.S. continues vaccines. and the We We with and products a Capital for and X have quarter outlined ambition momentum Health the of pursuit year. assets our investing of delivered strategy in indications at in General last EU PPH and growth Consumer and strategy and in Likewise, to cough once good business Medicines, than Win sales all Markets sales sales travel our for both other more again reported accelerated key than off, in February across Day in franchises another selected core €XX our our executing critical growth is new milestones with the double-digit transplant cold. doubled assets. further our Dupixent. noncore endemic on submitted divesting pay of growth several strong in resulted business in on of Vaccines greater

once X. third strategy, to strong first clear executing the cardiovascular trajectory R&D pipeline quarter set BOI growth. R&D midterm The on of to period Moving quarter again again. marks targets. as on point of growing XXXX, within discontinuation focus our on us the now activities. Play margin year Into our of prioritization of on deliver of at the our we results Slide another diabetes now improvement In and proof spend constant Win rebuild puts and is Specialty our the of to a due double-digit to of financial first EPS the investments Care lower rates grew a following

striving for the last recent Tidal. of Kymab, a years, in increased we pipeline. cumulative spending industry our way, acquisitions Principia, X and development of by In our are million the with immunology, Kiadis area priority exceptional Over assets we €XXX as our the and in funding an such leadership bolt-on R&D

key injectable from Our spectrum to the broad oral and topical. priorities, pipeline spans our most offering promising across diseases tackling MOAs modalities of to with a

where especially in and transformative with COPD, unmet as such medicines X to molecules potentially in include no growing dermatology as for highly Specialty as representing and more Care disease to management needs, type the than emerged mechanisms new and attractive have areas diseases, in enter early as XX now for addition markets respiratory, decades. we market inflammatory XXXX. Dupixent have that foundation the programs development These In the cornerstone in start X could

of John collaboration the in would immunology, development to course, I and build I'll by investments into another areas. to highlight development with over forward and quick that briefly these neurology to industry-leading wanted like to deal to reallocate subcu our serves key to mention I and the our through to facilitates do example expand on the hand prioritization. continue This give pipelines Partnering update. added Blackstone. to of R&D which growth aim further similar collaborations us M&A We Slide I and some a formulation, pipeline oncology during of allows portfolios to Sarclisa targeted to quarter. strengthen going us BD. position Advancing Our as in-house Sarclisa's expand. X. to both R&D our before

to us over So you. in here for summary, quarter first Sanofi. at really John, a strong

John Reed

you, Thank Paul.

through expand continue In supplement QX, external science capabilities. collaborations announced X we add deals to further best-in-class that pipeline. our We our pipeline to our existing that

our design our on tusamitamab now proprietary the develop to collaboration ravtansine, cancer lung build first-in-class technology. that's Seagen CCAMX-targeting our ADCs III molecule, collaboration with up for synergistically conjugate announced potential will with ADC momentum combine and proprietary advanced We to First, Phase Seagen's in antibody-drug technology an cancer. antibody ADC with monoclonal for agreement with targets. This to potent payloads exclusive X

and drug utilize research likely chemical and to to we our expanded while machine our also most discovery the to line and through We precision learning, lead accessing with patients across and patient pointing collaboration their a immunology. subsets from Exscientia Second, established time to With accelerate those accelerate optimization machine engineered the are oncology drug technologies Exscientia, benefit. to now for medicines medicine of discovery promises this spanning learning AI-based small potentially to collaboration discovery strategic of existing precision platform, selection. identification molecule relationship us

conventional agonists agreement of to and antibodies bivalent immunology established IgG X exciting efficiently approach seeking inflammation agonists and overcome cell service multivalent collaboration activity historical platform of the the potential Our developing to that stimulate of bind third platform receptors. collaboration targets has This unique is offers an class IgM some X Bioscience. limitations can technology We've with of IgM exclusive oncology antibodies antibody against develop targets. worldwide to IGM an when Their receptors.

targeting tumor improve clinical chasing cell our we depicted strategies IgM on of of and including of to announced commitments, terms of Slide of cell corporate we in broad ago, in are mission people's to single exemplify that in For Play rather current scientific the which science journey conducting Sanofi One receptor collaborations new social cells. for communities, a case its to XX. our in our not believe in eliminate immune our clarity, several towards T these types certain cancer on are to engagers, childhood activate factors, miracles each innovative Advancing antibodies wish strategic surface trials due strategy. engineered context responsibility medicines but of deaths vulnerable CSR to pathobiology, the innovating to The we treatment cancers. Sanofi, for fully to presented in Within develop this slide objectives. year embedded ambition lives. cancers Win ambition heterogeneity this molecular children. features the challenging At Today, is pediatric prognosis, pillar of

purpose and with we families. As their trial a ensuring leadership previously Head move Oncology the by clinical our was innovative the of partnered and impact objective Development, this result, feasibility Sanofi the Group, for vulnerable for that group of Adamson, the pediatric for with challenged advance creating strong who why clinical be sense Aided That's Oncology of of trials forward Pediatric design of addressed patients. cancers young institutions of for oncology is designs. issues by with trial patients to several real must practical leading has a Peter Head of these

combined only year, Speaking to XX, transplant-ineligible with to for and are patients, frontline X in eligible the we this half compared in like read ago. to molecules with development for molecules innovative of myeloma of expected MRD oncology summarize on negativity now newly Initial was in a Velcade in showing oncology, an building rate pretransplant. the Congress years unprecedented progress dexamethasone data ASH podium Slide myeloma in in the diagnosed REVLIMID, is XX the presentation patients trial advances just who multiple second few year. Sarclisa, transplant I'd with an shared making event-driven IMROZ at Starting a of out are portfolio last

in we're efficacy AMEERA-X, this selective lines and studies, the tolerability to amcenestrant for degrader observe our data Ib benefit presented to of For treatment third-line second at therapies. and we drug Phase as endocrine options. amcenestrant, not superior be of a II we second-line, exploratory the engagement In at breast strong practice SERD, metastatic oncology most few development, Phase the is our already these and target combined the often broad observed assess inhibitor oral in efficacy with women dose. or have of cancer of efficacy therapy. a The aromatase we other started the patients, call late did the XXX-milligram where a year. estrogen failed full have pursuing journey swing a receptor We once-daily different conference unfortunately, a excellent in CDKX/X tolerability Then clearly program took we combined robust with will trial, line with inhibitor where with half an compared population

the Now ahead breast enrolled And in combination the frontline of study for schedule. comparing or has fully CDKX/X either inhibitor cancer metastatic in in conduct aromatase with palbociclib AMEERA-X with some aromatase trial the an adjuvant cooperative setting, cancer setting, inhibitor then early amcenestrant the a features. of groups we have seminal with joined high-risk world's forces inhibitor-intolerant on tumors that in to have patients breast focusing leading oncology

amcenestrant AMEERA-X head-to-head enrolled and study its has patients. against puts Our tamoxifen adjuvant first

adjuvant opportunity the of the design to While the relatively market adjuvant by subset study standards. addressing a this population, quickly reach affords

for year's treatment remarkable. aims post-immunotherapy of lung to cancer of cell ADC long-term Additionally, nonsmall really at so data our promising will to quite treated high-expressing care with ASCO, cancer we tumors durability patients. molecule, but PD-X. lung combination also duration the observed become tusamitamab, in CCAMX cornerstone this second-line the results for become is first-line far in lung present a for Tusa not showing patients with therapy only standard in of The

to in and ongoing our effector I expected pancreatic, the starts additional XXXX. in monotherapy to expansion and cells this medicines, leveraging molecule CCAM-expressing without breast out immunosuppressive in lung cause are and half XXXX. finally, cancer, being eosinophils Then later trials of selectively second your as XXX's effects. T tested X decisions III and attention side indications In anticipate potential that year read pivotal SAR'XXX, of also T best-in-class to tumors, oncology efficacy inform starting ability that's combination other addition cells planning regulatory impressive to undue basket data our or draw killer to in in namely interleukin-X gastric for across early natural non-alpha with Phase cells We expand and

BMS aftermath of we by the compared of presented and the IL-X you the from pegylated remind ASCO where in non-alpha I a molecule, the IL-X in collaboration differentiated we to Nektar our that want attributes decision Now information discontinue to BEMPEG taking of slide their at to recent XXXX, event their BEMPEG, investor on Nektar's SAR'XXX.

the bottom deliver. biology not surprised receptor. of chain here, details molecule at the Unlike the our Nektar into BEMPEG, the line is struggled permanently engagement IL-X going selectively to single precision allows pegylation from that Synthorx without acquisition Now of the alpha a and site we're that that synthetic IL-X of for blocks platform

in pharmacodynamic native the causing unlike significant and clinic cells SAR'XXX, natural selectively that namely, what killer that the to expansions of CDX-positive IL-X's of does molecule, effector Our was thus or immunosuppressive cells data far contribute do, regulatory without T designed illustrate generated XXX to precisely it expands eosinophils toxicity. T Nektar cells

Xx XX, like validation achievements my Slide immuno-oncology. slide, for recent What of our pipeline to On highlight is of IL-X improved attributes a to Nektar during dialogue the show the we more of now of SAR'XXX QX. the engineered we molecule, I'd potential next-generation best-in-class here last the than and list data provide the in which We external accelerated which several has the believe over greater I authorities, Sanofi's Bill Nektar the clinical the we're can molecule, XX future medicines, differentiated Our hand of to that which with first-in-class for the frequently our non-alpha pipeline. reviews dose more that total Q&A health allows than dose index from become With therapeutic will the to efficacy. Sibold. that, us to in fall pipeline receiving IL-X, across drive have higher about granted

William Sibold

Thank you, John.

Care the with double-digit year It XX% up strong to with to in to billion growth performance. a quarter, €X.X start Moving is in Specialty our see exciting the solid sales. first

therapy. the in our first more in a are once Dupixent, billion, of with brand, over mega growing Paul the last still dermatitis blazing atopic truly in Dupixent's stellar on year's XX% €X.X globally, now patients delivered indication our beginning for immunology mentioned from Five first our years its of with immunology Dupixent QX. As there is are launch trail only the than XXX,XXX transformative quarter indications we adults. sales X% all again and portfolio. journey earlier, approximately market U.S., of by Across groups age at penetration into

eligible last least a event performance XXXX immunology the X.X about our expect anticipated at with in expansions. to new add brand by at million our More month, we indication highlighted As just minute. patients

grew Our the in first quarter Oncology launches, driven by including franchise in key Sarclisa X% at recent markets.

was you strong by generic facing competition. performance launch offset the As Jevtana know, in LOE Europe

As our about focused are highlighted news assets. excited by John, first-in-class on rich best-in-class on the we portfolio oncology emerging flow and

Disease driven sales by the business million underlying across of quarter reported €XXX Rare in patient Our an in increase base first the geographies.

were of remained in of Pompe Kevzara Sobi, strong Rare Rare order partner, the U.S., despite note, was higher X% Continued by year. impacted effect Aubagio. Blood Disease versus sales growth phasing sales Disorders lower our in last X%, in by up which grew offset were to other of franchises the quarter. sales growth the broadly Cablivi sales in the sales was XX% lower our in up the Of XX% in by mainly franchise, had the quarter. stable due sales Immunology Europe. to Neurology year. and with last line demand driven Lemtrada industrial uptick

XX. Slide Moving to

months A up like In quarter driver and XXXX €X.X in in reaching this Dupixent's €X this are the same start key with I'd including track sales are still period to sales XX% start, on at the the compared last below biggest considering strong strong is annualizing exploit incremental represents on in opportunities, year. even performance more the QX U.S. impressive, over growth QX With we reopened performance fully to offices the physician we strong since million Notably, billion. of pandemic. new of with further ex €XXX almost with emphasize of was outstanding performance severe Let's its X-year-old U.S., esophagitis, QX exciting indications, as eosinophilic have asthma of Dupixent's quarter. children to AD 'XX growth made in billion to focus as XX-year-olds Europe. close X- prurigo nodularis, submissions regulatory the the X XX% sales approval the since than for for the well to we progress gain around more including in first the launch to

XX. of diseases. persist impressive dynamics space Dupixent COVID-XX does benefit to Moving also inflammatory the demonstrate position from slide type The this panels pandemic to new seems molecules momentum the the the only in brand leadership the across impact the marketplace the in on Not and but for Slide the strong X of subsiding. XXXX, with entering

as we growth physician contribute fact, for the additional believe In Dupixent that options awareness. treatment market and for potential patients to as improved unlocking expansion incremental patient through well significant

extremely further diseases, in inflammatory our IL-X and targeting Dupixent's type unique are strengthen We X leadership action well mode selectively position positioned to of given IL-XX.

efficacy adults safety of We and patients. treating continue the settings and Dupixent, in to both demonstrate younger and clinical real-world

leadership type indications the across asthma expand the or spectrum. its atopic respiratory, diseases unlike type rapidly polyps, entrants adding by failed X Dupixent have dermatitis, continues Importantly, X new rhinosinusitis such as in dermatology and in with nasal which chronic to inflammatory new

our highlight let the Disease advances next some Now on in exciting business. Rare of XX, Slide me

Rare care for Our quarters the about in innovative standard by Nexviazyme leadership fully recently X late Pompe patients. the all in process Nexviazyme. into Nexviazyme patients making And the of the has launch, Xenpozyme. products, on launched half of on are Nexviazyme of in reinforced further position U.S. Only are remain focused with the and either we onset next X disease already starting appropriate or been

the to Xenpozyme deficiency quarter, March, opportunity late in may therapy urgent new therapy treat research of and we regulatory ASMD. you pathway or medical Japanese track obtained to acid governance be Sakigake designation, Xenpozyme, approval world's with As only development highlighted addressing our Sanofi's and under products the which promote for last innovative fast recall, medical I to sphingomyelinase the Japan, first is approved launch first indicated In needs. unmet

around for We working patients to to globally, the innovation are efforts ASMD from medicine advance the health and this diseases. including to launches and U.S., rare to life-changing with bring available now EU exemplify authorities our important Both world. the patients relentless treatments suffering make

the strong growth on update mainly the despite With that, to franchises. markets. Vaccines order usual across annual drive success This you global due a of in hand phasing our to over an keeps Rare dynamic us the in basis demand quarter-over-quarter on Thomas mid-single-digit I continued on patient trajectory Our business. accruals fluctuations to

Thomas Triomphe

Pentaxim Thank growth, driven to you, Bill. in back. QX This X.X% delivered with mid- in single-digit franchise, PPH our bounced guidance. where line was high the by performance China

from reassuring the endemic are the normal a strength also conditions when portfolio restored. strong recovery the is of of It and vaccine saw witness life easing restrictions. our franchise travel travel to We vaccines with

which flu about when in safety to And stock However, term, this due base for that business. with quarter flu we and on one sales the a in another XX% like flu may pre-pandemic. built local XXXX. endemic, In becoming decline the the the record for unpredictable. as COVID-XX slide, governments Shanghai booster to current we The last regain temporarily benefited is remains reiterate our COVID-XX. was speak confident high our we traditionally in level some impact and QX, that To anticipate due will we lockdowns vaccines travel like to year low COVID-XX year epidemiology extraordinary are from mainly demand I'd longer enjoyed conclude sales,

beyond standard our differentiated strategy In dose addition, formulation, vaccines, flu. have remains South Hemisphere that trivalent are influenza vaccines markets protection with on sometimes focused the high-value using mostly even while demonstrated

pivotal the I'm we solution all infants shared, already XX%. to of in of the a significant And trials. hospitalization Last hospitalizations most do slide, protection RSV. providing the published England of the progress New and past first protect XX.X% with infants RSV-related nirsevimab bring reduction detailed pleased all infants. impact month, Journal have Medicine against by made the common few results RSV leading a Next tremendous disease cause is to for months in that efficacy please. we nirsevimab RSV thrilled the of the besides cause are all LRTI, of showing Knowing the believe will by analysis by on the

dosing vaccines that benefit accelerated immunization vaccines fashion, predicted by stop III the understood one in This event, maternal to And is we'll maternal evidenced smooth an our As Regulatory December bring. setback of during clinical by EMA. all trials. last our Phase candidate being a the immunization have the experienced one can first the ride. review not authorities nirsevimab had was

the year ahead encompass this are We expect to monoclonal of later recommending on interested in Committee year, to licensed Vaccines In once them have make scope putting the antibodies Practices, by their recommendations nirsevimab. plan. and highly the decision Immunization review U.S., X EMA their Advisory on U.S. body position charter has in updated also nirsevimab receive a ACIP, the to

Lastly, a Phase that year. share the Olivier. I'm of schedules. to sets It the that, IIIb setting With study immunization in glad supporting nirsevimab benefits ease real-world to call generate will in start of I to pediatric our the this in data showcase implementation and strong data hand reinforce over will October its

Olivier Charmeil

Thomas. Thank you,

XX. Moving Medicine on to General Slide

very pleased industrial performance which our from €X.X with included billion, Medicines We to broadly are quarter. sales affair. in stable the were first General sales

first in of has constraint, consistently strategy core asset results the recent in delivered planned, deliver of would Excluding on our and our slight quarters. Med execution divestiture generated the positive as the and impact have to Gen supply continues quarter. focus the The growth

Eloxatin Soliqua, were and Our Rezurock, noncore growth in the strong Thymoglobulin core The but key of in in lower driven Lantus divestiture, of our are streamlining growth assets Praluent, the impacted Lovenox. sales reflected X.X% lower of impact on strategic quarter, our as lower VBP X product grew which which Taxotere X.X% the well decline performance impact assets sales of €XX and as ongoing with in and of million to Multaq, achieved of sales Sales double-digit by China wave line expectations. of efforts. the by the

noncore of down impact the were Excluding divestitures, X.X%. assets

reducing objective the number families vigorously profitability. of know, you and product with increase are the smaller to As efficiencies drive we

moving before, XX. to mentioned I've As Slide

in and slowdown Let's the quarter. focus of comparison the rest assets limitations in Biosimilar for supply a in world partially volume-based XXXX, also our COVID-related with performance. and the implemented demand, strong In core were Europe insulin comparing of impacted and be U.S. sales in with the XXXX. in the first on in decreased quarter procurement the impacting in competition the world, up offset are by X.X% of XXXX. especially of a X.X% high to May of the the rest growth sales the is China, region sales Lovenox performance base by of first Toujeo expected lower

and among to bidding in Lantus Group This with As enable higher will the us discussed price. Toujeo. at winners deliver the Sanofi volumes earlier, but was lower A

year decrease total full results, at in Lantus, to XX% and sales, glargine announced our Toujeo in we around expected As China by XXXX.

the Toujeo insulin of establish Looking in of Toujeo driver in large we to China ahead, our make the in as choice XXXX market and diabetes important aim to basal one expect beyond. China in growth and

the of in degludec primary We a share ATTD time head-to-head Toujeo will study at using and results range endpoints comparing tomorrow. InRange, as

performance with well-established Rezurock by Thymoglobulin. well strong as driven performance a strong as of transplant delivered franchise sales up the Our XX%

With results. in Julie. We sales the to EUROAPI I have institutions core patients, the our expanding deliver announced positive first CAGR performance who to assets in XXXX, delivered be was our innovative confidence the Medicine on In QX pent-up core stable report as strong call asset. of as about continued from Europe growth in systemic XXXX-XXXX, sales as sales already XXXX over multiple to relaunched reinforce core General of grow quarter in in Medicines now full recently excluding at the our continue professional Germany. Rezurock, where CGVHD period continue overall therapies. the XXXX the over of experience. demand our Praluent clinical that, hand deliver General reflects excited well to and to performance our prescribing roughly to Healthcare mid-single-digit conclusion, sales its rapidly pool new ambition it year failed reach XXXX performance due asset

Julie Van Ongevalle

that a report quarter very QX for are market above to second Thank we the trending glad in row, in growth. you, Olivier. I'm and

were market months Since a see this share, on we that ahead year, remember slide, more that than can XXXX. until Let's closed last you gap. This and X trending data is about shows we as of points this in QX basis, losing on as our as The key commitment, progressing, clearly continue of which to priority priority the I'll in XXXX to XXXX our early geographies. X execution on paying market that was while back raise the page. above our next grow we And below brands rolling have strategic bar. XX is come to off.

First, on to an Rx give I lines of switches. like would you OTC update to the our time

Cialis, QX. this busy FDA been and COVID-related start our in we For puts our has XXXX. further the Earlier company far it we AUT priorities. understandably, of journey, will launch and XXXX, in made on this before the very month, with estimated has feedback, No date this received end this

enough Tamiflu, flu rely their we study ready to flu needed our the so on the be minimum studies but seasons. we contract go, can to experience as For to that shared, low. X a were flu of Several has with the people very and prevalence we of continued disease,

we able an in planned. to to circumstances, use progress Given be as XXXX not these trial originally will actual

influenza we course, accelerate keep to be can that to studies done progressing. program the Of all continue without

opportunity As that flu note Tamiflu in to to the switches season. business same. result, remains the the a launch estimate the is we Important for XXXX-'XX

supply driven have we versus in XXXX. page, and of growth growth, 'XX also and our most double-digit resource our QX business strong cough first, QX more doubling reallocations is and our and levels a in looking the Last at points. responding doubling by are pre-pandemic ensuring by, not but maximum and informed performance and with next that growing strong favorable net to third, availability current I'm This delivered performance, powerful cold given X categories growth priorities very geographies XX% products the a data; our way bold teams how a our announce to consumers; least, understanding proud than I'm engage our our -- On the sales thrilled this price capture effect of constraints. creativity increased and in with to of brands opportunities. consumer includes market current agility strategic an challenges, the second, increased

to I'm quarter, extremely a and proven higher strong comparison also I ahead, over Looking that, have to base. The QX ending. focus robust market growth cough expect the XXXX be season working. to that and it our very is will next to now proud strategic the this of experience on after And normalized that a continue we more quarter I on our Jean-Baptiste. priorities hand our achievements. delivering team With CFO, my further have cold

Jean-Baptiste de Chatillon

Julie. you, Thank

products XX%. and growth SG&A OpEx, affairs. grew XX.X% sales. to than bps at able the growing So rate, rate favorable slower XXX quarter, is in Within Gross leverage the significantly within improvement the Care Specialty from shift P&L. addition on margin higher we of industrial pace sales resulting in also exchange of deliver were efficiencies to in our our portfolio to EPS constant And a at supported by tax lower effective

Turning XX. to Slide

particularly growth and business. be to its positive potential, API independent line dividend Sanofi grow independence of allow will incremental February only own a we also In pharmaceutical in line XXXX. creation and XXXX, worldwide addition It will The through the the EUROAPI EUROAPI, in to is The margin a will €X.XX the EUROAPI, to more capabilities patient shareholder in Europe manufacturing its to leading for secure created to EUROAPI development ingredients. CDMO gain capacities in in simplify as its the on of and in will slightly to also player medicines help agility value APIs efficient, context of BOI our on supply active not strategy have announced spinoff Sanofi's unlock and but global operation. with Win XXXX, development Sanofi's in Play leader in is With increasing transaction production. with an the become in company of on of support to care. CDMO ambition essential This this create its project, shortages proposed

XX So already for contract going X-year of on host sales. held XXXX. signed on October plan are accounting a further the we provide May We supply have information in to forward. to deconsolidation part assets EUROAPI an manufacturing now assets agreements and on CDMO call

its progress Global we our distinction on the committed a companies patients Indeed, aims Sanofi's sustainability Ratings us of Sanofi unit. as across income one ambitions, category wide ranked of of of in communities, committed medicines profile specific to to has great Health XX. work polio on of it carbon ESG sustainability-linked in creation March again, Play linked And eradicating this Well, KPI revolving to we the across key facility is access sustainability In it are our one our issuing Moving is In with of leading the therapeutic XX of with countries. strategy, It's the credit a time. lowest billion areas Sanofi range some a team our Win had fully first embedding highlighting provide the the social of in to renewal Global XXXX, health to reducing doing teams. on our finance coupon global and recognized from The XXXX all while recent of our bond. XXXX, to continue most linked Slide XX targets and the our company. ESG to ESG S&P amount footprint. our happening the as €X

expenses dynamics update outlook We and XX. for Now on on Slide expected across the business sales XXXX.

core of the record maintain the you slide, across left including business expected Dupixent, for our of season the sales growth On Gen see GBUs, of and product momentum CSG strong and can of drivers from Med. part the continuation flu

same brands market sales grow to business, time, in entire nearing progressively rates. before, geographies, growth stabilize. overall above GBU the market to resulting for we also foresee expect the Gen CHC communicated priority only in but key we in As Med At

be consolidated May So that EUROAPI this planned consolidation Gen business. is sales in The reduced EUROAPI by third-party planned going will currently amount Med the XXXX. Upon forward. listing, are sales in

part right on the margin slide, efficiencies to we improve to gross basis. expect product the due On mix to full of continue and year the

based ETR XXXX half legislation. Slide line will be estimate we of XX% geographic the R&D grow capital evolution business, Gen we expected million with in We it year. However, slide, our current generate be in estimate product in continue the CHC of happening mix. given to in and the around XXXX. and streamlining This is keep now second €XXX On final the of our are expenses approximately majority expect disposals first our weighted my of on with the to half tax And XX. our as strategy. that gains Med to the to

of exchange, On EPS We a our X% year impact to exchange handing double April margin on expect currency I'm constant positive our XX% digits to BOI based achieve call see now exchange also rates. On a for financial XXXX Paul. X% targets, at of business the back to to in the low guide rate. we year. we average foreign XXXX the grow full to way XXXX

Paul Hudson

thanks, J-B. Well,

We and of few data to XX-month shared a on immunology received On be our the the our I planned understood. the weeks before updated quadruple sales slide, by the end more trust final strategy to at our that I of latest presented flow. you news data were the feedback ago with really touch let's pipeline our ambition BTKI to tolebrutinib pipeline difference our neurology is immunology decade. QX tolebrutinib back ACTRIMS. And becoming events, compelling rich franchise the I than shows on that was look and emerging for well We and because

immunology recognized way as the We our are to being on company.

upcoming to Turning events.

we CSR are our built during Since as you our of planned to the event about X. ESG for with business of July late forward part XXXX to deliver our initiatives on We telling are we making the contract within in organization, these have looking first society strategy progress approval new priorities. our embraced our

disease hemophilia patients. the to revolutionize has fitusiran potential the and event, to we in-person We this the pivotal trial highlight the that, of the that Journal with treatment New an for call let's investor pipeline event Phase We'll hemophilia also blood results disclosed efanesoctocog the also alfa mid-July. factor positive review data A II With published in thus ITP Medicine. data At now the full just Q&A. open for plan far want rilzabrutinib England of in to our rare our hold on

Eva Schaefer-Jansen

Thank Instructions]. you. [Operator

two have to options You participate.

raise So option your the icon X, the screen. at bottom click hand of

by when read open of the that bottom to time, your be submit and us clicking two, your screen be notified you then will ask at your question. Q&A the questions will sure line icon question microphone. by your Or your our You your please by is option unmute At panelists. make

go the let's to Now first question.

Operator

The at first come UBS. Laura Sutcliffe question from should

Laura Sutcliffe

me. can you Hopefully, hear

Paul Hudson

Yes.

Laura Sutcliffe

Great.

in your the booster vaccines any active just of is of substance the characteristics kind be the taught next past steps potential new on the ongoing market. there of there? or on secondly, months COVID That great. the avalglucosidase and whether dispute end the with what then have over are would if Firstly, this And a you have appetite is thoughts EMA the any booster few for road maybe

Paul Hudson

back I'll moment. Thomas, a Thanks, booster vaccines? Okay. come avalglucosidase COVID appetite Laura. in for to

Thomas Triomphe

now demand is COVID-XX you've that as a very comes first-generation world in Well, having Well, of everyone have bigger And level Laura. when supply well, is the boosters. had COVID-XX strong indeed of to been right the price than our results to it's you, Thank it we vaccines. now and COVID-XX you clear for as the amount seen is get boosters. know

data them. whom supply are to partnerships. markets. second-generation markets provide going And forward XXXX, have with variant are in and interested, variants. believe that, we'll available We Beta to start make data We the going coming we come we multiple the different partnerships. which second course, very based quarter show Once are and soon. foremost, generation licensed, on it it of And first to QX course, are our the very that's the moving to countries going supply boosters those to will all of on make That's across to once with available, important our we this the to by being booster COVID-XX we

we far when as go that's COVID-XX comes as So to it boosters.

Paul Hudson

Bill, Thomas. comments on you, avalglucosidase? Thank any

William Sibold

question. the for you Thank

look, this standard we with science, all, believe data. complete We're we said going disease. they Pompe of far. all are of the side have the disagreement is side at for and First the care right right we of And opportunities, become are of exploring so what believe the to looking in that that on we

Paul Hudson

Bill. Great. Thanks,

Operator

Graham at comes question Parry Next from BofA.

Graham Parry

Great.

So the first one is just on the guidance.

quarter. So you've obviously had a strong

full gains gross Is you're your half. margin capital but just €XXX shift I half geopolitical more first flagging was your million, by at didn't benefits noticed year guidance sort of that also second Your all. uncertainty? guidance you than upgraded

now. if caution of ESMO then it So behind on that's on at year said AMEERA-X, the full the And it And not didn't sort coming secondly, efficacy. he just until think what's show I looks as moment? clearly superior

numerically AMEERA-X there some AMEERA-X the into ESMO there? to settings? does So from that we guess, that that anything AMEERA-X, just imply positive I be looking read was should in out for, trend So

Paul Hudson

capital gross gains margin. Thanks, Graham. guidance, J-B, and

Jean-Baptiste de Chatillon

It's Graham. only on, QX. Come

to love it's confidence, nothing the I special Effectively, in right you're the confidence and So love your there's and showing year, raise. you're to early so. do team, I and the

but crisis, you us beyond. navigating deliver on are count 'XX in to We and can

really to signal nothing So on this.

Paul Hudson

a John, Thanks, J-B. on comment Okay. AMEERA-X? quick

John Reed

think become estrogen and amcenestrant was of patients, statistically experience are nuances we data late-line for able really presentation of point releases year. did physicians the not the later is have cetera. the are at now meeting the shared mutant, report a Graham, this what selected Yes, wild-type disclosed, be journey. other at these see you'll significant independent a to ER, like see the showing that cancer already care I press more being et most may to this receptor their more subsets those and the of else in that And in course, cetera, submitted versus which by population, than all that between nothing in them standard and et We difference once

Paul Hudson

Thank you, John.

of watching is because earlier. year towards that's key tolerability earlier we be we As know very the differentiator profiles. we will as informative later what out lines, a That for go we're relative course, this head

Operator

Bernstein. Next question comes Wimal at from Kapadia

Wimal Kapadia

the first My please. on nirsevimab just is question trial,

to tract sig achieve lower in reduction failed infection. you hospitalization stat RSV-associated So for respiratory

for commercial had And on point? of that feedback Russia, as Ukraine. result a how What to really second specific molecule. that data if So then and you've just on be far my is the curious so question interested impacts your I'd hear. potential just thinking

You trial. mentioned the COPD MS

curious how data not into timelines filing data -- just into So translate shifts will timeline. delayed timelines

elaborate that a if maybe just you on that, So would be great. could bit little

Paul Hudson

Wimal, X-month very you. chance Okay. excited We're Thomas? the infants. to data, protect about thank all

Thomas Triomphe

very Indeed, Wimal. III question, positive Phase the for trial. Thanks

in and have to. let I'll we've against Phase endpoint. me then folks different to we plus prespecified succeeded come talked data, a the So by restate IIb XX% Phase III Again, back the showing of perception the reduction hospitalization

very are hospitalization. we it was we Phase with doing there year we powered outcome was know to well the knew to that the prespecified. with from the and why that's alone secondary but work regulators, But we've positive times, that drugs data feedback. committee, of so we as be able III plus not possible, II have on Again, very demonstrate multiple many And that in very, order said You shared advisory III when were endpoint X. not Phase Phase

birth very of this less can from implement that in in so X. you with cohort newborns year well advisory hospitalization you're show see If X/X a year where many cause to with products in you not full lends are the X, of from committees. or There hospitalization. going That #X payers

not it's So data, finished. we're show happy and to very the where that's at,

We XXXX. There market journey, end and some of showing door. the moving are very in more excited Again, next XXXX, potential. Congress about for will expecting in having nirsevimab the very May launch EMA soon and authorization the forward be very exciting the data so ESPID in year at

Paul Hudson

interventions I Yes, of this talking people, Thomas. on my experience learning as that you, type fast. own deliver Thank well very mean, to impact that there's few that health from and population

John, So very about see are like. you what Ukraine. that why can people excited looks Russia,

submission But circumstance. there's some in clinical the So been are running companies time difficult track. such trials challenges of for in on all lines actually course, a

John Reed

Indeed.

track moving with a Russia. teams conducting still outside our the and the to those affected heroic sites sites western staying on on submissions territories, the good with have patients lose in the we've to where then patients XX% that We're we we are expand into for example, if study and in so through of shared MS previously. our And efforts really to taken country some or are neighboring our roughly of mitigation say, obviously efforts parts track combination are tolebrutinib. would of day, and are far, I molecules, for well global territories About on those we in We that keep data. making in extra submissions But case in add as our we've clinical patients study countries recruitment active. U.K. Ukraine, into studies

Paul Hudson

John. Yes, thanks,

invited Herculean they already, but supervision it's remind make to not that by being mentioned think privilege people and just a need meetings also Had a get of to I investigator one but deliver weeks global great our stay studies. of the the meetings, how on is Bill these important few John ago and by a patients effort to it everybody track. has John to investigator to least sure

help the sure everybody to make doing timeline. we of the miss So can only do company course, we not don't but that patients, we in what

Operator

comes question at Richard from Vosser JPMorgan. Next

Richard Vosser

Two, please.

you consumer vaccine end Just could for flu. we secondly, the update Could development and of to program sort of an an flu growth don't level forward? what we think do there? of that on us going on mRNA the Clearly, pressure on by about? a then think development And going and see comp talk season. And the market going pressured the just of easy I in being year? the consumer, -- detail. mentioned. about cough what's should easy you the the update market more before how And perhaps you are give the anticipate very on But on the was cold

Paul Hudson

update? program flu mRNA Thomas, Richard. you, Thank

Thomas Triomphe

full and in All speed.

product that So have into results as after before, Phase I/II I/II go mRNA to trial. in we HX year quadrivalent are we starting the a provided flu modified to the initial going we discussed XXXX, go Phase last

are make more LNPs and We this to that. year opportunity start studying And this results on between and -- keeping speed last optimization. we -- to want that we more code year's take by full sure

we're of excellence. the center gathering on about very science So excited mRNA the

journey. flu you it development, mRNA going comes when to be a know, it's to As

our way seen, X. have the event go, I our especially to look if That shows Richard, and into there some the You mRNA mRNA still the of as the II focus right of the there well at from some Phase company. data potential terms find systemic of the recent need show They But that is competitors. in Grade to in as LNP, still we that's is that the on opportunity. a adjustment of lot cell probably adverse mRNA

Paul Hudson

predicted been the forward that up a mean, it as it we've lost in a certainly, anybody We everything said we I feel couple sort really of transparently. we we out the on Yes. be while go the shouldn't times, December Thanks, challenges think right I it. competition clearly and And and on X we bit of we've have later to facts last caught little to year. laid like handed And actually what may face. party mRNA, would takes the and differentiate understand Thomas.

way to in I'm long a always positively And we're a I think going everybody, is proud a come we've So surprise actually. year. very which team of good thing. the

market consumer -- market Julie, Now development.

think I Richard you is next? suggesting had great but what's a quarter X,

Julie Van Ongevalle

can more the X, strong we you and of I is and It course, mentioned, with that performance the an easy QX still, that, the behind almost we go market levels. to season to think Thank be of last as QX, and year, the will much, market you quarter Richard. cough growth us, QX very normalized what seemed believe but cold say

a was us growth a high also year for that versus QX is what even double-digit QX XXXX versus Now even can for I specifically, us this and single-digit say 'XX. growth QX

want focusing are key this So by we again and geographies. again, pre-pandemic our above to we on is continue levels, where brands and core

normal will market the remain we yes, but more So quite levels. optimistic, go to

Paul Hudson

Again, Thanks, well Julie. on quarter X. done

Operator

Wolfe. question from Next Anderson Tim is at

Timothy Anderson

questions, of please. couple A

a also failure ultimately and confident failures So those uncertainty Or viable as Health. of and make recently this will drugs of do And it market? the second ever class? is you a given bit on X more the failure that's AMEERA-X to class Roche, on to add SERD, by the Consumer just question that are your at least as

would the one across OTC point? in underlying the complicating What plans of and durability answer not switch setup like will a decade, reason delay we in program factor to the what rid get are? a a divest be your the And pharma you least And great Given at at definitive this to here your of vaccines that? with business get is XXXX would for it Consumer to seem Health. on

Paul Hudson

you. do to want go answer? thank have John, So SERD at questions. Tim, the you Great another

John Reed

that the an Yes. sweet we the the receptor we're early of mean, is spot was going growth. driver estrogen the confident in of the therapy Tim, for be I really beginning, to tumor felt lines important from that where SERD

So both very But opportunity the associated late the we place remain really, We early confident is them. use for right with lines and the in the patients company. line risks where a real that, the is took that. the that's swing for knowing to

Paul Hudson

There's a to Yes. learn. still lot

the the get to we half richness. second congresses the more get we As in year, of

I think it's clear.

the said the on you challenge class going were later reason going going be It's And can't it, activity. to why tolerability. interesting. it's mechanistically really the But do think well to to really I no interesting lines a earlier. given There's get John. be

And hold For lines. do same the nearest to they earlier competitor, going the example, our the those challenges differentiate tolerability things into are forward. that will

answer in the earlier forward We if see interesting too. continue won't consumer you. over So look be is? efficacy Jean-Baptiste, lines, the to to the on the who it so question to to class to that, you has then, winner like

Jean-Baptiste de Chatillon

for question, thanks Yes. Well, the Tim.

what are asset. the on seen working are course, we think not stronger time, just had better and remember of building looking position Julie And a at we our business. question, really you really 'XX. en a changed we since I since? same back, building to happened really the think, But you've exposed, what has stronger really, and December route I Well,

has we And our decision-making, of business. the this changed. happening, really and in. It huge it's And agility, this happening it's carving So autonomy that's on in level of necessity course, is our meantime, bringing which in go position. with in not well, really a

glad So are right we yes, are we with where now.

So no change.

Paul Hudson

Thanks, Jean-Baptiste.

Operator

Next Citi. Verdult at question Pete from is

Peter Verdult

Two Pete Citi. questions. Verdult,

price But in Just suggests momentum U.S., net the fantastic double-digit calculation Dupixent pressure. low first, our globally.

the Graham's wanted through going second And previously on that we then better And IL-XX your COGS about feeling just follow-up a and perhaps when I margin announced quick P&L? call to Dupixent, that I target. forward, and midterm cash considering you're to see team the the want the the pipeline, improve that. and at know in knows So especially sail significantly how on I when to understand free launches? your to the with full in business question. focus coming you're comfortably from actually flexibility update rebating quick everyone well might set efforts on the But a same you'll invest to you flow one, do past time, think

at where So the the next? midterm this are objectives is, platform or planning CMD early later be question your year And could would that revisited? you be

Paul Hudson

Bill? Okay. Pete, thank you very much. Dupixent,

William Sibold

product, see programs Great. are highly so the and perspective position question. Pete, sales. have It's you it first industry. forth patient in thanks seen planned with I indications, long-term it's net the the pretty favorable for cetera. We what historically And impact an quarter. a throughout for Dupixent. you the obviously, really, we from of from mean, growth we've regularly, in the QX that anticipated et just on the new competitors, access assistance

gross to downward some expected. be continue things that's are to pressure on here. but out of So as nothing though And net, the tracking usual there's ordinary

Paul Hudson

year and which we I think touched the you if a least. from Yes, competition And on probably we're I remember, -- away at it. remind,

the education Some of and competition market. terms the good the is noise in in

William Sibold

around seen So need to mean, AD. that's Paul. to. wins? who need I We Yes, a great world need It it the counting forward competition in the as have into growth guess accelerate and we're market. asthma. market. come it's competition. We've the I what are best product think We point, competitors helps we in help to it profile, on where the the looking with it We grow

Paul Hudson

Jean-Baptiste, COGS Bill. you, CX? Thank and the

Jean-Baptiste de Chatillon

'XX process. front. different the 'XX. to it deployed changed takes I Remember, our said, Yes. in Nothing the on and has that it as will be new delivered, sites, time deploy And during

P&L will will get see impact the in you you full our So and starting 'XX.

Paul Hudson

I of Thank around advice, may a the sort future investor always, point right, company very new fast. I think But that think we to Good next you as try some We'll the any as direction. And Okay. from be. And for coming we're -- time do chapter suggesting doing, you're could you. should reflection opportunities hope it's Pete, clearly, is have right in around about CMD and builds get you. important it in the for what conversation. we and I but you I excitement for the update what

for out watch that. So

Operator

question Next Luisa from comes Hector Berenberg. at

Luisa Hector

China, where in strong we growth if touch could on the quarter, wonder you I XX%. had

of the from outlook the you new there. perhaps the little on pressure but lockdowns the have then do guidance side for on update rest just So bit and of positive a because incident your year launches,

deal, China? So very we can we the just on Are to for where perhaps in full Blackstone many And growth opportunities expect positive there. other similar year there from this? your could deals touch interesting like pipeline see the

Paul Hudson

you, Okay. Luisa. Thank China growth? J-B,

Jean-Baptiste de Chatillon

Yes. bit Yes, rebound. see we are quite a that

heard from some vaccines You've rebound.

our You've were seen we well the performing also board units. that business different quite in across

player this volume. and go we'll us, of on So to being market important is a

piece? impact -- this everything and winning the growth you You in that China. is EBP update negative been our we in volume, the stronger mind and had to on maybe game and us On want makes remember lockdowns really I Thomas, getting playing we where you around to maybe quite which in of and wanted Shanghai, win us have stronger of successfully,

Thomas Triomphe

you, Yes, absolutely. Thank J-B.

you're right. Luisa, So

-- it on of a you have and I have by was quarter the strong driven rest said, We world, seen as PPH China. and

difficult is know share. market We're very to city COVID-XX is predict well And how and Pentaxim/pentavalent duration that in pair gaining You combination China. for is lockdowns, long. which there which and doing

Of drop. course, vaccination to of of the And people you you can center. duration don't expect the have that lockdown, the point go an exact therefore, during immediate

less about talking immunization, we're babies. than X-month-old However, pediatric

people as is go removed, and their first So soon bring there. the as lockdown newborns

shifts but the be between up as as some showing quarter-to-quarter, removed. quickly is going soon to it's we lockdown catch So very

Paul Hudson

Thank opportunistic, you. Blackstone, as for but stay clearly we Luisa, open-minded.

agile these staying differentiated. mentioned moving have many course, produce we We're of to think data, best market subcutaneous. believe more cases, but things. going the it upfront I for hope CDXX, is to my around in we In I the we

it. how was also to simple over be upcoming have the What do to subcutaneous way return, or compete a best help our is a to be able positively when accumulate market a one. when ourselves it's it So to get and question I data really some that but in know will very the we get do efficient to we think an it's differentiated? years know to we to realistic best when

think just frankly, it but are, importantly, shows think opportunities that I we So open-minded how for is we there some Sarclisa.

forward. we'll that quite It's actually. So as exciting we watch go

Operator

at Goldman. is from Keyur Next question Parekh

Keyur Parekh

you. Paul, one for

broader valuations biotech thoughts Clearly, capital updated this of the to kind allocation, have M&A your love on corrected would priorities here. a seem bit Just fair year.

McLaren, how of much year? this wondering feeling potentially focus question from that using that's about increases So Any one. bigger the are just seems still in of thoughts an host has given especially the So of investor balance as how XXth the partnership aggressively course May a forward, a The these more with rest newly the number of the look you're transactions your then over your the are are of fairly broader XXth kind on And bolt-on either perspective? are seeing, sustainable very or across into sheet you consumer number lastly, X% going kind May? increases of you price healthcare Question universe like reported XXXX. planning just so two of that's announced Paul, But to guys event for think consistent we plus kind you price on far. in Julie. interest interested

Paul Hudson

Thank Keyur. as always, Thank you. Okay. you,

M&A, us. So for nothing well, changed as really for

disciplined. pretty pipeline. add to I the looking we've We're been think to

And the us fallen. size. right. about and never the It's building It's about that been always it's have It's prices right picking target We're it for been about I doing we're hasn't the some been think the thing. right for right assets. areas. in right us. changed it out always But that clear

We stays that on as if thing, at I've the for we we'll of the least been spend very here. reason. a since it and time usual. think the beginning, see business been just good lot And I move. right same That's since

they only So cost opportunity Julie, is. may good it's less, price sustainability? us the how but still about

Julie Van Ongevalle

Sure.

We're we the are question. the for you situation very Thank you. because, closely price. obviously monitoring thank yes, So increasing

hit are at are adapting looking And competitive always where et we consumers. our but cetera. actual increases, to consumer price fair we elasticity. possible material behavior, staying raw We're as So by prices needed, our as

consistent very plus something the been again, But have it's monitoring to think something so I question, doing answer but we're it's your coming now, we're, we what -- X% And will the yes, be points months. the closely, X on. in

Paul Hudson

Brendan, you, Thank a you. question. answer Thank Julie. you to get the chance

just So -- for thing. partnership, dates, about then to specific can his important and is on question a partnership answer talk you why the few about maybe the the but seconds and the

Brendan O’Callaghan

Thank Will do. you.

led Brendan primarily everybody. So O'Callaghan, Sanofi the he's areas the blood at year, XXXX, therapeutic leading which organization and rare responsible disease. across Care oncology, disease, last in rare since before that biologics I good morning, organization Specialty good QX Industrial immunology, I'm the of afternoon, manufacturing Affairs Bill for since supporting

assets XX than not before, work And XX with portfolio we've a scale to a I'll almost of give and our first year. supporting billion up deliver to that XXX CMC and perspective sites pipeline his almost and across the patient of work million day, R&D XX,XXX We're John single take doses some teams new on-time met organization an very XX we closely we colleagues just of with so a minutes close SKUs doses more sure in you in maybe on supporting time. reference. X in right So make supplies We to every course, few my scope products launch all for units. business of countries, over

-- Our we priorities these deliver. are the at in patients Industrial clear areas that Affairs our And most it's and here: cost of at key efforts. expect time focus product we the support on supply very priority can our in quality competitive improvement reliably,

capabilities improvements, we our who partnership journey. a the where us we at as and mindset internally the drive both experts improvement looked that's And various external so sought to levers as can of about. set a inspiration, And accelerate well McLaren help with came have we bring perspective, to from as fresh us

the asset both cross-functional insights in last can racing analytics in operate maximize to they to data technology we're capability engineering, first They've help that, ability stop precision key represented over where famous clearly, this improve to last the skills and high we'll which grid. and our taking on single-digit XXX difference utilization know, and to that that improvements X% select over in of production rapidly, our focus with lines, separate also our full leveraging their sites. McLaren help efforts. production our and leveraging And our year best bring manufacturing a the the by on environments, across of place the make data you number mindset, up teamworks, of We base then network, started pilot, that, teamwork As efficiencies. one competitive, our pit and that most mastered is through and the productivity of racing fast-paced high-performance from of us and expanding delivered internally us year with And XXX learnings to cost out their continuous a lines. we're driven deploy improvement, reaching a competitively to almost speed to will sense strong mindset, innovate

Paul Hudson

you. thank Brendan, Well,

there. opportunity your took You

exciting a more portfolios it, is how But to efficient important the Just and agile, And we go externally improve to more this heart we bring sense through opportunities can think a aside, effort lines. productivity is big do on speed it, it's efficiency own we internal be move move cost simplified hard and And R&D through attention of and really more I as on affairs. aspiration we it for of it's externally fully are. -- and productivity to too. it articulate that at the as as and modernization than we and opportunities -- can have be joking operational quite opportunities, appreciate to industrial But to our realize people these will people business, an probably internally. all fun too. And organization, time

So for us. big a real opportunity

Operator

Next Cespedes. question Florent from comes

Florent Cespedes

from quick Two Cespedes Generale. ones. Florent Societe

RFI or divestment update Olivier, on maybe you of a the gave this also Dupixent, you this color [indiscernible] also simplification market. Olivier. us maybe give the I and X. second you examples for COPD some because in follow-up in multiple have, you and because front the trials could the clinical regarding great on terms the front. be trial on think you itepekimab I notice some there think, And could where So would strategy sclerosis on situation your Ukraine elaborate trials for First But question, an X stand? with on

this on would great. front color be any So

Paul Hudson

Great. Thank Olivier? you.

Olivier Charmeil

Yes.

you, thank Florent. So

distribution me to a to map, in on of bit countries line in our simplification. in of simplification. that a how roughly model. XX color bit terms a we now We let give through say not in in both advance are So the little operate progress little I road geographic say terms plan would in you we of

not products, it's countries. no small small no anymore -- So

it's We early, footprint. far -- our geographic relationship is of new too are we but more the our get have course, simplified the drastically signals And preliminary with that positive. distributors

goods. simplification portfolio, the cost is Regarding absolutely but decrease in key as XXXX had we which more simplify than end to families. Starting product know, our XXXX, of of also of or to XXX you

to plan at the go through XXX with well to the moving in discontinuation of are we XXXX objective end with divestiture, So in and XXX products, of of pruning. this year our course, line both,

the element life order make drive to cost colleague, the down people bit So our of Brendan, line my important a his I more really and little an goods think with easy. in And it's plan. of and in

Paul Hudson

specifics the think to And to add? to give and with COPD, on anything on a going Olivier. bottom it business Again, to good that. just Yes. R&D. clinical heads line Russia, on Thank touched perhaps to the I you, cadence really between back think getting affairs industrial we're is the industrial the to teamwork really I into us added trials, resource that's redeploy but and John, Ukraine with opportunity unit important affairs, to

John Reed

of a are our The answer the is Ukraine. in terms of in of lower percentage bit that exposure COPD in largely, quite risk terms I Russia say for is would or patients found

have covered data. doing efforts other submission on to if to in talked best we're already so just basically that I as So keep We're no to timelines. change recruitment before, and we study, expand patients any some lose making patient our we territories about

Paul Hudson

you. Thank

Operator

Mark Purcell at comes question Stanley. from Morgan Next

Mark Purcell

two for me. So

you XX% of looks to efa for fun Firstly, we over fast when the could in question, Elocta. could space move patients alfa? bleeds that any of think CCAMX of Is one of And understand want breast share the XXth for second of X for you should opportunity the the expect And the July and about What factor the help you comment I take could the that breadth we but the target pancreatic on cancer? the clinic? efficacy from in a chemotherapy how don't ADC of the the should replacing into event, alfa? in with And outstanding, to in cancer opportunity first in there and collaboration from lung terms us targets efa CCAMX market mid-teens versus collaboration? the achieve Seagen then target?

Paul Hudson

Thanks, breadth tusamitamab opportunity? the John, Mark. of

John Reed

quite We studies adenocarcinomas, breadth cancer. indications try Obviously, of with we expressed percentages those lung different both quite large the cell microtubules, agents that for gastric, we're sensitive is number combination most in to CCAMX historically cancer, think a pancreatic, that nonsmall the as is the to to those agents, being opportunity monotherapy for think understand the advanced starters, really because target that, lung and extensive. some pilot quite different better the in doing other But in of is broadly in breast, are types. tumor in

frontline chemotherapeutic watch of we experience get later as substituting is with nonsmall one this be. about for CCAM have in I we'll broad in to cancer So think could for that we're the cell foundation better things much thinking of -- lung PD-X, the opportunity some some year we how where combination agents, for are a

II Phase end those for watch data So year. the towards the of

we for In disclosed the terms are collaboration. that have Seagen, targets not what of

molecule that. but fast a say hazard I we development. dedicated it'd And can can't any into So we'd moving premature the about very that we be probably quickly might clinic, when have more we're as as to think possibly in to

Paul Hudson

Thanks, John. Bill, efanesoctocog?

William Sibold

Yes.

and outstanding. you called the for think question, Thanks thanks. it So I

-- the bleeding A you population, We with think start disease. I'll A seen that's severe Medicine would hemophilia hasn't of first when a are That's in that Journal offer again, I statement into time, of belief. with for it England mild the same something special. the that New transform a agree We before. with hemophilia something the their market normal, can

no to you think outcome the and on covers that normal? to differently have. become company, patients well. side should have We had there And the as factor another market of have a to. hemophilia evolve? what we think I is that A the in think even best how market you will little segment, if fortunately, anything bit going for as that about segment, other going close demanding it a want market hem can. our prophylaxis possible market that is it Efa fitusiran, what to is A, A be than hopefully, is hands to the about that community down, convenience? hem the is which the asset, does other have the that belief the have Will start a it they a The efa -- you ever to Or question offers factor shifting is So is towards be, prophylaxis market

optimistic. So bit a little to year. up we're We'll our this detail extremely come more later into we event as get

Paul Hudson

Bill. said, Yes. Well

then, our nearest the in they're go beyond that competitor, And patients. And that is a standard. new course, point that's of the weekly other on it, go of with never it been we're convenience It's that to offered the because look nonfactor. just normal, to quite enough going before. interesting, have I convenience really, won't or think Monthly which where on will that's XX% be. nonfactor isn't really

opportunity share So put share factor on I real on you, -- the the some say the beyond maybe there's goes pressure assumption, the depending to goal Bill, is. what that ultimately that

raising Mark. for thanks So that,

Operator

question at Guggenheim. goes to next Our Seamus Fernandez

Paul Hudson

Seamus, did you? we lose

Operator

around, would at give not Peter... is -- I Seamus to Welford it Peter If Barclays sorry,

Paul Hudson

Jefferies.

Eva Schaefer-Jansen

Jefferies.

Operator

Jefferies.

Peter Welford

It's right all though.

questions. So two

is simplification. thing first The on just the

€XXX additional forward is be guided I have of think I'm brought that of And consumer there to this And very think I going just disposals to a had and as Gen will that these around of that should simplification the to additional you nirsevimab. we gains talk of years. this then curious, really of over few going you additional think disposals said to should a much gains Med are from on what you've portfolio? that you've that's you've thought now health prior million. raised gains should -- on next the about? most we planned of because those the Or you coming capital or years in like from you year the got think something cadence we top be what this found sort

the obviously, change. the the You and decision half mentioned second EMA in U.S. ACIP

how Given about to nirsevimab Or of potentially obviously ACIP here, obviously various breakthrough the of season guess, more countries, from we we as for think into from therapy possible? groundwork to winter European 'XX to I should use have should potential the think rapid as recommendations going, we And realistically also to that? are time the to of 'XX you countries the the 'XX? this have get with by a some turnaround of we U.S. potential 'XX laying the get European a

Paul Hudson

Thank capital Jean-Baptiste, gains, Peter. cadence? you. disposals Thank and you,

Jean-Baptiste de Chatillon

you. Thank Yes.

the financial much You a is successfully. signing through we month we a just cadence a that have are in our linked this condition. good deploying And to very almost that are fact to update deal the read strategy very

or of relentless So or necessarily on effectively, a on the nothing It's -- the CHC. execution impact not is the Gen upside. more But bit it's both. else than less Med

map are on fast. road of We on our top really executing

Paul Hudson

company -- and the isn't connected Sanofi. -- everything IA look of -- future important It's and at to an sort transformation is It's we I And the can we do be just sense. that I It strategy and long-term make sure Yes. think us. to drive it think in point, company for a the to disposals to the to the the GBU leapfrog have simplification accountability of it, because that jump will it. -- makes of efficiencies to around

RSV comment maybe on Okay, nirsevimab season? you a Thomas, and from so the

Thomas Triomphe

think accelerating to from 'XX already know on 'XX. nirsevimab about And that like acceleration. to you we're I pillar,

X we review going for look -- where will half realistically that which of XXXX, though, to the the at a you the the outcome. then think ready ACIP like in second has we're its as I you mentioned, the time important question So changed other year. U.S. in ACIP remember the are in to very submit it. charter, is And body file. regulatory And file

I So say on, first RSV sales for on about seasonal a knowing that And in of launch disease, nirsevimab. are would talking that is it's XXXX I we part. from there expect, the your will

Paul Hudson

Thanks, Thomas.

place good a bring the probably that's a to Thank today. for interest the for you think to I to conclusion. questions us and everybody

Just by few a of way in performance thoughts, strong QX.

You've get the to updating seen progress year. it as again, into Pipeline look further we forward again.

exciting to of these perhaps and think a prepare exist very us in that's organization, what I looking to running getting that's although didn't we you R&D now it's ago. to coming talk fact like And productivity gains miss don't launches I think -- means us can about So that's positively we're surprise. allows as few we're I to double out how set to that And all the together. deliberately excited because we important well that down think about years for it for an not

time today. thank you, So the for everybody,

Sanofi (SNY) 28 Apr 222022 Q1 Earnings call transcript